The HTT CAG expansion mutation determines age at death but not disease duration in Huntington’s Disease

Keum, Jae Whan, Shin, Aram, Gillis, Tammy, Mysore, Jayalakshmi Srinidhi, Elneel, Kawther Abu, Lucente, Diane, Hadzi, Tiffany, Holmans, Peter ORCID: https://orcid.org/0000-0003-0870-9412, Jones, Lesley ORCID: https://orcid.org/0000-0002-3007-4612, Orth, Michael, Kwak, Seung, MacDonald, Marcy, Gusella, James F. and Lee, Jong-Min 2016. The HTT CAG expansion mutation determines age at death but not disease duration in Huntington’s Disease. American Journal of Human Genetics 98 (2) , pp. 287-298. 10.1016/j.ajhg.2015.12.018

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (528kB) | Preview

Abstract

Huntington's disease (HD) is caused by an expanded HTT CAG repeat that leads in a length-dependent, completely dominant manner to onset of a characteristic movement disorder. HD also displays early mortality, so we tested whether the expanded CAG repeat exerts a dominant influence on age at death and on the duration of clinical disease. We found that, as with clinical onset, HD age at death is determined by the expanded CAG repeat length with no contribution from the normal CAG allele. Surprisingly, disease duration is independent of the mutation’s length. It is also unaffected by a strong genetic modifier of HD motor onset. These findings suggest two parsimonious alternatives: 1) HD pathogenesis is driven by mutant huntingtin but, before or near motor onset, sufficient CAG-driven damage has occurred to permit CAGindependent processes to then lead to eventual death. In this scenario, some pathological changes and their clinical correlates may still worsen in a CAG-driven manner after disease onset but these CAG-related progressive changes do not themselves determine duration. Alternatively, 2) HD pathogenesis is driven by mutant huntingtin acting in a CAG-dependent manner with different time courses in multiple cell-types, and the cellular targets that lead to motor onset and to death are different and independent. In this scenario, HTT CAG length-driven processes lead directly to death but not via the striatal pathology associated with motor manifestations. Each scenario has important ramifications for the design and testing of potential therapeutics, especially those aimed at preventing or delaying characteristic motor manifestations.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Additional Information:	Released with a CC BY-NC-ND licence
Publisher:	Elsevier (Cell Press)
ISSN:	0002-9297
Funders:	Medical Research Council
Date of First Compliant Deposit:	30 March 2016
Date of Acceptance:	21 December 2015
Last Modified:	17 Nov 2024 15:00
URI:	https://orca.cardiff.ac.uk/id/eprint/86871

Citation Data

Cited 82 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item